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Abstract 
Background 
Stent design and technological modifications to allow for anti-proliferative drug elution influence 
restenosis rates following percutaneous coronary intervention (PCI). We aimed to investigate 
whether peri-procedural administration of corticosteroids  or the use of thinner strut cobalt alloy 
stents  would reduce rates  of binary angiographic restenosis (BAR) after PCI.  
 
Methods 
This was a two centre, mixed single and double blinded, randomised controlled trial using  a factorial 
design. We compared (a) the use of prednisolone to placebo, starting at least six hours pre-PCI and 
continued for 28 days post-PCI,  and (b) cobalt chromium (CoCr) to stainless steel (SS) alloy stents, in 
patients admitted for PCI. The primary end-point was BAR at six months.  
Results  
315 patients (359 lesions) were randomly assigned to either placebo (n=145) or prednisolone 
(n=170) and SS (n=160) or CoCr (n=160). The majority (58%) presented with an ACS, 11% had 
diabetes and 287 (91%) completed angiographic follow up. BAR occurred in 26 cases in the placebo 
group (19.7%) versus 31 cases in the prednisolone group (20.0%) respectively, p=1.00. For the 
comparison between SS and CoCr stents, BAR occurred in 32 patients (21.6%) versus 25 patients 
(18.0%) respectively, p=0.46.  
Conclusion 
Our study showed that treating patients with a moderately high dose of prednisolone for 28 days 
following PCI with BMS did not reduce the incidence of BAR. In addition, we showed no significant 
reduction in 6 month restenosis rates with stents composed of CoCr alloy compared to SS. 
http://www.isrctn.com/ISRCTN05886349 
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Introduction 
Inflammation  is one of the key mechanisms of restenosis after intra-coronary stent implantation [1]. 
An inflammatory cascade results in neo-intimal  proliferation which, if excessive,  results in 
restenosis. Drug eluting stents (DES), offering local delivery of immunosuppressive or anti-
inflammatory drugs2,  have been the most successful  means of  reducing the need for target vessel 
revascularisation compared with bare metal stents (BMS) [2]. Despite the introduction of DES,  BMS  
are still used in patients at low risk of restenosis and in patients for whom a short course of dual 
anti-platelet drug therapy is desirable(e.g. when there are concerns about risk of bleeding). DES are 
also more costly and so BMS may also be favoured for economic reasons in some health economies.  
There have also been concerns about stent thrombosis and accelerated neoatherosclerosis, 
particularly with first generation DES [3-5].  
Issues for  DES include drug delivery and polymer coatings (which themselves are associated with an 
inflammatory response). An alternative approach using systemic anti-inflammatory agents has also 
been tried. Corticosteroids mediate their effects  primarily through the modulation of the cytosolic 
glucocorticoid receptor. Expression of anti-inflammatory proteins is upregulated and expression of 
pro-inflammatory proteins repressed [6, 7], both of which may reduce restenosis. 
The pathology of restenosis in BMS begins early after PCI and inflammatory reaction within the first 
30 days is important [1]. Thus, both the timing and duration of corticosteroid therapy may be 
relevant to lowering restenosis rates and it may be important to suppress the inflammatory 
response prior to stent implantation. Corticosteroids have been studied in different contexts, 
including balloon angioplasty with and without stenting, and  with variable duration of treatment 
both pre-procedure or post procedure. Results have been mixed [8-10].  
Another important factor influencing restenosis in BMS is strut thickness. In stainless steel (SS) 
stents, restenosis occurs less frequently with thinner struts [11, 12]. These findings have influenced 
the drive towards the use of higher radial strength materials such as cobalt chromium (CoCr) alloys 
that allow reduction in strut thickness. Early registry studies supported this concept reporting 
restenosis in 15.7% of patients with cobalt alloys [13, 14] but there has been a lack of randomised 
data. 
This trial investigated whether administration of corticosteroids (started several hours prior to PCI) 
or the use of CoCr stents  would reduce the rate of binary angiographic restenosis (BAR) after PCI.  
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Methods 
Study Design  
Using  a 2x2 factorial design, a two centre, randomised controlled trial compared the use of 
prednisolone to placebo and CoCr to SS steel alloy stents in patients admitted for PCI. 
The trial featured a mixed single and double blinded randomised controlled design. Both the 
patients and the physicians performing PCI were blind to the prednisolone/placebo allocation but 
only the patients were blinded to the stent allocation. Patients were block randomised to 
prednisolone or placebo prior to angiography and subsequently to CoCr or SS stent once eligibility 
was confirmed. To provide a loading dose of prednisolone prior to the procedure, randomisation to 
prednisolone or placebo occurred in a 1:1 ratio prior to PCI. Patients eligible were randomised to 
either a CoCr or SS stent in a 1:1 ratio. Allocation of patients into intervention groups was achieved 
using a closed envelope system, managed by a research team working independently of the clinical 
team. 
The primary objective was to show that prednisolone (compared with placebo) or CoCr stents 
(compared with SS stents) reduced 6 month BAR, defined within the stented segment plus five 
millimetres proximal and distal to this.  Secondary objectives included investigation of the  effects of 
the interventions on a number of pre-specified angiographic measures (see below), impact of highly 
sensitive (hs)-CRP, and assessment of patient safety. Major adverse cardiovascular and 
cerebrovascular events (MACCE: death, myocardial infarction, cerebrovascular event and target 
vessel revascularisation) were also recorded.  
Setting 
The study was performed in two tertiary cardiac units in the United Kingdom, The James Cook 
University Hospital in Middlesbrough and the Royal Infirmary of Edinburgh. 
Recruitment 
Patients eligible for the study were identified from the elective waiting list or were awaiting 
angiography after an acute coronary syndrome (ACS).  Inclusion criteria for the double 
randomisation were: awaiting PCI for symptomatic coronary artery disease (elective or acute); 
documented myocardial ischaemia; coronary angiography demonstrating at least a 50% reduction of 
the luminal diameter (by visual estimate) in at least one native coronary artery; any lesion for which 
the operator (consultant interventional cardiologist) assessed a non-drug eluting stent was 
appropriate.  Exclusion criteria included proposed use of a drug eluting stent in the study lesion(s); 
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left main stem stenosis >50%; primary PCI for ST elevation myocardial infarction; corticosteroid 
therapy for an alternative reason within 30 days of study enrolment; contraindication to 
corticosteroid use; previous recruitment to the trial; non-cardiac disease likely to cause death within 
six months; out of region hospital transfers. 
Trials procedures  
Prednisolone 40mg/day (or placebo) was started at least six hours pre-procedure and continued for  
14 days, stepped down to 20mg/day from days 15-21 and 10mg/day from days 22-28. 
Patients were pre-treated with clopidogrel. Coronary angiography was performed via femoral or 
radial artery puncture. After sheath insertion, a bolus of heparin was administered (dose: weight 
related with a minimum of 70u/kg). Before angiography, 200μg of intracoronary nitrate was 
administered. Lesions in large vessels (visual estimate of ≥3mm) were treated according to 
randomisation between the Multilink Zeta™ (SS) and Multilink Vision™ (CoCr) stents (Abbott 
Vascular, USA).  Additional lesions in small vessels could be treated with Cypher Select™ stents 
(Cordis, USA), eluting sirolimus but as the trial progressed other second generation DES were also 
employed.   Patients could be enrolled into the trial with lesions in small vessels if the operator 
thought it was reasonable to treat with a BMS. 
Due to dual oral antiplatelet therapy plus oral corticosteroid use, all patients received empirical 
proton pump inhibitor cover (lansoprazole 30mg/day for 28-days) for the duration of the 
prednisolone course. Optimal medical therapy with beta-blockers, angiotensin-converting enzyme 
inhibitors and statins was encouraged; use of other agents was at the discretion of the attending 
physician. Patients were treated with aspirin 75mg daily indefinitely and clopidogrel 75mg daily for a 
minimum of four weeks. 
All patients randomised were routinely brought back for repeat angiography. Quantitative coronary 
angiography (QCA) was performed as at the outset for all treated segments. 
Angiographic measurements were made before predilation (baseline), after the stenting procedure 
and at follow up using the Philips Inturis™ system by a research fellow (ZA) who performed the 
analysis independent of the clinical information.  Measurements were made in diastole and 
performed in two orthogonal views.  The contrast filled guiding or diagnostic catheter was used for 
magnification calibration. QCA measures included: minimal luminal diameter (MLD); reference 
diameter, derived as either an average of the proximal and distal  reference diameters  or the 
interpolated diameter derived by the software for the selected segment; percent diameter stenosis; 
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in-stent restenosis, defined as ≥50% diameter stenosis within the stent at follow up; in-segment 
restenosis, defined as ≥50% stenosis within the stented segment or within 5mm proximal or distal to 
the stent edges; acute gain, defined as the difference between MLD after stent implantation and the 
MLD before PCI; late loss, defined as the difference between the MLD after stent insertion and the 
MLD at follow up; net gain,  defined as the difference between acute gain and late loss. 
Biomarkers and monitoring of blood glucose 
Hs-CRP and glycated haemoglobin (HbA1c) were measured at five time-points:  at study entry, on 
the day of the procedure, at seven days, at 30 days and finally at six month follow up. Due to the 
potential problem of hyperglycaemia in patients randomised to corticosteroid treatment, all patients 
were given home glucose monitoring kits. Prior to hospital discharge they were instructed on the 
correct use of home monitoring. They were also educated on normal values and provided with 
contact details of the research team, in hours, or cardiology on call team, out of hours, for support 
and advice if their blood glucose recordings were high. 
Safety 
All patients were monitored for bleeding or for hyperglycaemia. Bleeding episodes were classified 
according to the Thrombolysis in Myocardial Infarction (TIMI) study group criteria for bleeding[15]. 
Adverse events were recorded according to expectedness and relatedness. 
Statistical Analysis 
The sample size for a 2x2 factorial design was calculated to detect an absolute difference in in-
segment restenosis rates for both the stent and  drug comparisons from 30% to 15%, assuming 5% 
alpha, 80%  power and  15% loss to follow-up, indicating 137 patients per group  (548 in total), and 
assuming no interaction between comparison groups. The planned sample size was not achieved 
and 315 patients were recruited within the constraints of unplanned complexities for patient 
identification and recruitment. The power calculation for the study was revisited prospectively 
before analysis of trial data and informed by recent evidence. Assuming restenosis occured in 30% of 
patients, and that both chromium cobalt stenting and prednisolone might halve the risk of 
restenosis, the average ‘intervention rate’ would be 11.25% and the average ‘control’ would be 
22.5% within each comparison group. Assuming alpha of 5%, the trial had 72% power to detect an 
absolute difference of 11.25% between groups, using a two-sided test (nQuery+nTerim 2.0) 
Analysis was performed by the principle of intention to treat (ITT), with analyses conducted 
according to assignment at randomisation[16, 17].  The intention to treat principle allows for 
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modification due to missing data, for which there is no completely satisfactory remedy since strong 
assumptions are required regardless of the approach taken[18, 19].  Primary inference was based on 
the primary endpoint analysis as a difference in proportions, using Fisher’s exact test [20] with 
statistical significance at the 5% level (2-sided), for combined stent groups and drug groups. Analyses 
of all secondary endpoints and adjusted analyses were considered supportive to the primary analysis 
so no adjustments for multiple comparisons were made. 
Sensitivity analysis of the primary endpoint was performed at the level of the patient and lesion 
using generalized linear models (GLMs) with separate indicator variables for steroid and stent 
groups as well as their interactions. Secondary analyses explored changes in angiographic measures 
using GLMs [19, 21] and the role of covariates such as CRP level .  
Patient demographics and study endpoints involving categorical variables were estimated using 
Fisher’s exact test; continuous measures were evaluated using Student’s t-test where appropriate, 
otherwise suitable non-parametric tests were used.  
Ethics and governance 
The conduct of the trial was subject to local site and London Multicentre Research Ethics Committee 
(MREC) approvals (ref: 04/MREC2/061) and registered with UK Trials (ISRCTN 05886349). 
Results 
Between January 2006 and May 2012, 315 patients were recruited and 359 lesions treated. The trial 
initially recruited mainly elective patients in whom angiographic status was known but over the 
course of the trial most patients underwent PCI immediately following angiography. In addition, a 
rapid increase in the use of DES made recruitment a challenge (see consort diagram, Figure 1). The 
mean age was 60 years (range 37 to 87 years), 85% were male, 42% were elective PCI cases and the 
mean number of lesions treated was 1.14 (range 1 to 4).  Groups were similar at baseline, with no 
significant baseline differences (Table 1). Of 315 patients, 308 (98%) received the treatment 
allocated to them and there were no instances of treatment cross-over. 
Angiographic measures 
These are shown for primary target lesions in Table 2. There was no difference in stenosis by any 
measure pre or post PCI, or at follow up. This was also the case when the data were analysed using 
the interpolated reference diameter. Across all groups, average in-segment diameter stenosis was: 
70.3% (95%CI: 68.8% to 71.7%) pre-PCI; 6.6% (95%CI: 5.9% to 7.3%) immediately post-PCI; and 
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35.2% (95%CI: 33.3% to 37.0%) at final follow up. Acute gain was 2.07mm (95%CI: 2.02 to 2.13mm), 
late loss 1.04mm (95%CI: -0.98 to 1.10mm) and net gain was 1.04 (95%CI: -0.97 to 1.12mm). The 
results were qualitatively the same for all lesions. The cumulative distribution of stenosis in target 
lesions is shown in Figure 2.  
Endpoints 
The primary endpoint of binary angiographic restenosis is reported in Table 3. There was no 
difference in restenosis between treatment groups. In-segment average restenosis across all groups 
was 19.1% (95%CI: 14.7% to 24.2%).  However there was significant variation within the individual 
treatment combinations (varying from 11.7% to 26.4%) and a significant interaction was identified 
within a general-linear model.  For in-stent average restenosis of target lesions the log-odds findings 
(x) were: 
x = -2.024 + 0.804.drug + 0.999.stent - 1.555.drug∙stent 
       p<0.001           p=0.096         p=0.039         p=0.015 
where drug is an indicator variable for prednisolone, stent is an indicator for stainless steel stent and 
drug.stent is the interaction term for stent and drug combined. Findings were qualitatively similar, 
regardless of the restenosis definition taken for target lesions or use of hierarchical models including 
all treated lesions.  Analysis of stenosis percentage (y) using a general linear model did not find an 
interaction. 
y = 33.40 + 3.11.drug + 3.20.stent – 5.82.drug∙stent 
      p<0.001         p=0.26         p=0.25          p=0.12 
Findings were qualitatively similar, regardless of the restenosis definition taken for target lesions or 
use of hierarchical models including all treated lesions.  The explanation for these findings is 
apparent in the comparison of cumulative stenosis rates comparing the treatment combinations 
(see Figure 2).  Although there is no apparent difference over much of the distribution, there are 
apparent differences in the tail at the 50% stenosis point.  Thus the finding may be an artefact of 
selectively dichotomising a continuous outcome and may not be of clinical importance. 
There were no important differences in any other study endpoints, adverse or serious adverse 
events (Table 3). 
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Bleeding 
Use of prednisolone did not influence the frequency of bleeding episodes: 7.6% vs. 5.5% for placebo, 
p=0.50). Almost all bleeds were minor and mainly related to femoral access (2.9% vs. 2.8% for 
placebo) at the time of the procedure. There was only one major bleeding episode (per rectum 
bleeding requiring transfusion). This occurred in the placebo group during the index admission and 
study medication was stopped.  
Biomarkers and hyperglycaemia (Table 4) 
Hs-CRP measurements were not available for 16 patients. The pre-PCI hs-CRP measurement was 
≤5mg/l in 213 patients (71%) of whom only 28 (13%) had a raised CRP at day 7.  Use of prednisolone 
was associated with a suppression of hs-CRP response at day 7 (-5.98 mg/L, 95%CI: -8.35 to -3.61, 
p<0.001) with a small rebound at day 30 (2.71mg/L, 95%CI: 0.78 to 4.65, p=0.006). There was no 
evidence of longer term changes at six months. There was no correlation between lowering hs-CRP 
and stenosis diameter at follow-up. 
More patients had home blood glucose levels greater than 11mmol/l in the prednisolone than 
placebo group during follow-up: 22.9% vs. 6.9% respectively (p<0.001). This finding was apparent 
qualitatively in diabetic patients: 55.0% vs. 28.6% (p=0.17), as well as in non-diabetic patients: 18.7% 
vs. 4.6% respectively (p<0.001). In the majority of cases, dietary advice and reassurance was 
sufficient and there was no significant difference between the groups in use of additional oral 
hypoglycaemic therapy, insulin or need for study medication to be stopped. Glycated haemoglobin 
(HbA1c) was also monitored at five points during the trial.  There were no clinically important 
differences between treatments during the trial. 
Discussion 
This trial was designed to address two separate questions. Was there was any benefit of (a) pre-
procedural systemic corticosteroid therapy and (b) the use of thinner strut cobalt alloy stents in 
preventing BAR after BMS implantation?  At the time of trial conception, both were seen as 
promising especially as there was concern about longer term safety with DES[4]. We found no 
benefit from the use of 28-days of prednisolone started at least six hours pre-procedurally or from 
the use of cobalt chromium stents.   
Compared with previous randomised studies [9, 10]  of corticosteroids, one of the key differences in 
design of this trial was the use of pre-procedural steroids and duration of treatment for 28 days. In 
the study by Lee et al., a single pulsed dose of intravenous methylprednisolone pre-procedure did 
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not confer any benefit in reducing restenosis in BMS [9]. In The Immunosuppressive Therapy for the 
Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS) study, prednisone 
administered 72 hours post procedure for 45 days in patients with elevated post-procedural CRP 
levels but normal pre-procedural CRP levels resulted in marked reductions in restenosis [10] with 
benefit extending clinically to five years [22]. There were only a small proportion (n=28/213) of such 
patients in our study, although our post procedure hs-CRP levels were measured at day 7. Our 
steroid protocol was designed to ensure therapeutic levels of anti-inflammatory activity before the 
initial injury from stenting as well as the resultant inflammation. Notably, we did not see any 
association between reducing hs-CRP and lowering restenosis. Our findings suggest that only a 
minority of elective and urgent patients fulfil the requirements of the IMPRESS protocol. Moreover, 
in routine clinical practice, the choice of stent at the time of the procedure cannot be determined by 
what the hs-CRP might be a few days later. Even in patients treated with BMS, the logistics of 
arranging for a routine hs-CRP measurement at 72 hours and then determining the use of steroids is 
difficult. 
Our findings also differ from the most recent meta-analysis of five studies investigating the role of 
corticosteroids in reducing restenosis rates [23]. Separate analyses were performed for two trials 
involving balloon angioplasty alone [8, 24] and three involving BMS implantation [9, 10, 25]. 
Corticosteroids did reduce restenosis following BMS implantation (RR 0.60, 95% CI 0.37-0.97). Two 
of these trials, the study by Lee et al. and IMPRESS have been discussed above. In the Cortisone plus 
BMS or DES alone to Eliminate Restenosis (CEREA-DES) trial, the study endpoint was not 
angiographic restenosis but rather a combined clinical endpoint of major adverse cardiovascular 
events (MACE).In about half of these patients CRP was raised post PCI, defined as >3mg/l, and there 
was a significant reduction in MACE (23% vs. 8% for prednisone treated, p=0.03) but it is not clear 
whether this was driven by less restenosis; target lesion revascularisation was 12% vs. 8% (p=0.23) 
for BMS alone (n=125) compared to BMS plus oral prednisone (n=125) [25].    
In both IMPRESS and CEREA-DES, the incidence of a raised CRP prior to treatment was higher than in 
our study (28%), suggesting that this might be an important feature to identify a group of patients 
likely to get a clinically important effect. Even though we included a relatively high proportion of 
patients following an acute coronary syndrome our results suggest that upstream steroid therapy 
will have no impact on restenosis in a population where the pre-procedural hs-CRP is not known. 
Both IMPRESS and CEREA-DES utilised a high dose steroid regimen (reducing regimen of 1mg/kg for 
the first 10 days, 0.5 mg/kg from day 11 to day 30 and 0.25mg/kg from day 31 to 45). They did not 
include patients with diabetes. In our study, we included patients with diabetes and this influenced 
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the steroid regimen, which was selected after discussion with our endocrine team to provide an 
effective anti-inflammatory dose used in other areas of medicine using a lower total and maximum 
dose of steroid in the early phase of treatment whilst minimising the risk of metabolic side effects. 
However, it is noteworthy that the results of the IMPRESS-LD study suggested that higher dose 
intensity for a longer period of time was required to reduce restenosis. The “low-dose” regimen in 
this small study itself included a loading of 1mg/kg for the first five days of treatment [26]. This may 
partly explain the difference in our findings. Prednisone (which is metabolised to prednisolone) was 
well tolerated but in our study, with more patients, we saw an increase in hyperglycaemia in 
patients on prednisolone, even amongst those without known diabetes. The potentially greater anti-
inflammatory activity with higher doses of prednisolone may therefore come at the cost of increased 
adverse effects. It is also possible that any benefits from an anti-inflammatory reaction might be 
countered by a positive effect on tissue proliferation. 
We also compared the use of thinner strut cobalt alloy stents with stainless steel stents. In The 
Intracoronary Stenting and Angiographic Results Strut Thickness Effect on Restenosis Outcome 
(ISAR- STEREO) trial, thinner strut SS stents compared with thicker strut stents  with a similar design 
had significantly less late lumen loss and BAR (15% vs. 26%, p=0.003) [11] . Similarly the ISAR-
STEREO 2 trial showed that thicker strut SS stents with a different design resulted in more restenosis 
compared to thin strut stents (31% vs. 18%, p<0.001)[12]. We tried to minimise other stent design 
factors by using stents of similar design (Multilink) but composed of the two different alloys.  In our 
study, there was no significant reduction in restenosis rates in the thinner strut CoCr stent. The 
difference in strut thickness was more marked in the ISAR-STEREO trials (50µm vs. 140µm) 
compared to our study (81µm for the  CoCr vs. 90-125µm variable strut thickness system for the SS 
stent which is thicker in straight areas and less in areas where the stent needs to bend).  It also may 
be that the expected reduction of restenosis due to reduced strut thickness with CoCr might have 
been countered by some other unknown factor.   Although our study did not show an advantage for 
the lower strut thickness stent using the CoCr alloy, it did not show a disadvantage and there may be 
other advantages from using the cobalt alloy, especially in improving trackability.  
Only one other single centre randomised study from Brazil has compared the influence of metal 
alloy (SS vs. CoCr) on restenosis. In keeping with our findings there was no difference in this 
outcome [27]. Their study design was different from our study in that both types of stents were 
implanted in the same patient but either in different vessels or in the same vessel if a gap greater 
than 10 mm could be left between the stents. There was also a larger proportion of patients with 
diabetes (36%) and higher rates of restenosis (34% vs. 32% SS compared to CoCr, p=0.80) than in our 
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study. Moreover, a range of different SS stents were used in the comparison group with a 
considerable range in strut thickness. There is scant experimental data on the subject. A small non-
randomised animal study comparing SS (120µm) and CoCr (90µm) stents implanted into normal 
porcine coronary arteries did not find an advantage of CoCr compared to SS with regards to late 
lumen loss and neointimal area from histopathological samples [28]. 
Our trial, although factorial in design, was not powered to detect a stent-drug interaction but 
nonetheless found one for the binary angiographic restenosis outcome.  Within the stainless steel 
group, there is a numerical reduction in restenosis by prednisolone whereas the opposite occurs in 
the chromium cobalt group. The weight percentage of nickel and molybdenum is higher in 316L SS 
than CoCr [29] and the release of these metal ions may trigger local immune and inflammatory 
responses in susceptible individuals [30]. Whilst this may provide a plausible basis for a stent-drug 
interaction, it is more likely that this observation is a chance finding.  
Study Limitations 
The change in the pattern of PCI delivery over the course of the study, with a shift towards more 
acute cases and ad hoc PCI had an adverse influence on recruitment. Many patients were not 
eligible for the second randomisation. This was compounded by the rapidly increasing use of DES 
use, largely the result of a National Institute of Health and Care Excellence (NICE) recommendation 
that DES should be used in arteries less than 3mm in diameter or lesions greater than 15mm in 
length [31]. Patient concerns about side effects of prednisolone and the need for repeat coronary 
angiography were also factors. This ultimately led to the recruitment target not being met. We 
approached approximately four patients for every patient who consented to the first randomisation. 
Of those who consented, only about 1 in 3 was suitable for randomisation after angiography. 
However, based on the results observed, it is unlikely that a statistically significant difference would 
have been achieved if the recruitment target had been met.   
Another potential limitation is lack of operator blinding to stent type. However, this would not have 
been easy to achieve considering the different appearances of the stents used and the primary 
endpoint of the trial, BAR, was assessed without knowledge of stent type deployed. Hence we do 
not believe this is a major failing. There was no core laboratory analysis of the angiograms but 
analyses were performed by a single research fellow separate from the clinical team. Statistical 
analysis was performed independently from the clinical team. 
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Conclusion 
Our study showed that treating patients upstream with a moderately high dose of prednisolone to 
cover most of the period of inflammation associated with restenosis in BMS did not reduce the 
incidence of binary angiographic restenosis. In addition, there was no significant reduction in 
restenosis rates with stents composed of cobalt chromium alloy compared to stainless steel. 
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Figure 1. Consort diagram 
 
 
 
*Physician directed 
†Failure to deliver study stent 
‡ Saphenous vein graft treated (study exclusion criteria). 
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Figure 2. Target lesion stenosis at six months 
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Table 1.  Baseline patient characteristics 
 
 Placebo, N=145  Prednisolone, N=170 Drug Stent 
 CoCr, n=65 SS, n=80  CoCr, n=90 SS, n=80 p p 
Actual treatment 64 (98.5%) 79 (98.8%)  87 (96.7%) 78 (97.5%)   
Elective PCI 26 (40.0%) 35 (43.8%)  37 (41.1%) 34 (42.5%) 1.00 0.73 
Male 56 (86.2%) 68 (85.0%)  74 (82.2%) 71 (88.8%) 1.00 0.52 
Age, y 60.2 (9.6) 60.0 (8.5)  59.5 (10.3) 62.2 (9.7) 0.54 0.23 
Height, m 1.73 (0.08) 1.74 (0.09)  1.73 (0.09) 1.74 (0.08) 0.89 0.38 
Weight, kg 85.5 (17.6) 87.5 (15.4)  88.9 (18.8) 86.7 (14.7) 0.50 0.82 
Smoking status          0.67 0.53 
never smoked 22 (33.8%) 30 (37.5%)  33 (36.7%) 24 (30.0%)   
ex-smoker 19 (29.2%) 30 (37.5%)  33 (36.7%) 33 (41.3%)   
current smoker 24 (36.9%) 20 (25.0%)  24 (26.7%) 23 (28.8%)   
History of hypertension 35 (53.8%) 42 (52.5%)  50 (55.6%) 35 (43.8%) 0.65 0.26 
Family history of IHD 40 (61.5%) 42 (52.5%)  50 (55.6%) 45 (56.3%) 0.91 0.57 
Previous MI 9 (13.8%) 10 (12.5%)  8 (8.9%) 12 (15.0%) 0.73 0.50 
Previous CABG 3 (4.6%) 0 (0.0%)  1 (1.1%) 1 (1.3%) 0.67 0.21 
Previous PCI 0 (0.0%) 3 (3.8%)  5 (5.6%) 7 (8.8%) 0.06 0.29 
Previous TIA/CVA 1 (1.5%) 1 (1.3%)  3 (3.3%) 4 (5.0%) 0.19 1.00 
History of peripheral VD 1 (1.5%) 4 (5.0%)  4 (4.4%) 0 (0.0%) 0.74 0.75 
History of LVSD 2 (3.1%) 7 (8.8%)  3 (3.3%) 5 (6.3%) 0.62 0.13 
Renal disease 0 (0.0%) 0 (0.0%)  0 (0.0%) 0 (0.0%) - - 
Diabetes (I or II) 6 (9.2%) 8 (10.0%)  13 (14.4%) 7 (8.8%) 0.59 0.47 
Insulin diabetic 1 (1.5%) 2 (2.5%)  2 (2.2%) 0 (0.0%) 0.67 0.68 
HbA1c, % 5.75 (0.85) 5.86 (0.97)  5.83 (0.87) 5.71 (0.50) 0.75 0.88 
Hypercholesterolaemia 61 (93.8%) 72 (90.0%)  76 (84.4%) 70 (87.5%) 0.11 1.00 
Cholesterol, mmol/L 4.9 (1.1) 4.6 (1.3)  4.8 (1.3) 4.5 (1.0) 0.46 0.04 
Creatinine value, µmol/L 91.1 (17.4) 94.0 (18.8)  90.5 (20.3) 93.4 (15.5) 0.67 0.15 
Troponin, μg/L 1.35 (4.65) 4.63 (11.54)  1.39 (2.75) 1.98 (5.52) 0.17 0.07 
CRP, mg/L 6.31 (14.53) 8.32 (13.11)  5.39 (11.77) 6.36 (15.07) 0.35 0.35 
Number of lesions          0.46 0.72 
1 59 (90.8%) 71 (88.8%)  77 (85.6%) 69 (86.3%)   
2 4 (6.2%) 9 (11.3%)  12 (13.3%) 10 (12.5%)   
3 1 (1.5%) 0 (0.0%)  1 (1.1%) 1 (1.3%)   
4 1 (1.5%) 0 (0.0%)  0 (0.0%) 0 (0.0%)   
Indication for PCI         0.58 0.81 
elective 26 (40.0%) 35 (43.8%)  37 (41.1%) 34 (42.5%)   
unstable angina 11 (16.9%) 6 (7.5%)  14 (15.6%) 14 (17.5%)   
non-STEMI 25 (38.5%) 32 (40.0%)  34 (37.8%) 29 (36.3%)   
STEMI 3 (4.6%) 7 (8.8%)  5 (5.6%) 3 (3.8%)   
GPIIb/IIIa type          0.88 0.21 
none 38 (58.5%) 47 (58.8%)  53 (58.9%) 44 (55.0%)   
Abciximab 26 (40.0%) 30 (37.5%)  37 (41.1%) 32 (40.0%)   
Tirofiban 1 (1.5%) 2 (2.5%)   0 (0.0%) 4 (5.0%)     
Lesion length, mm 14.0 (6.4) 13.3 (7.0)  13.8 (8.2) 14.5 (6.4) 0.49 0.98 
Stent length, mm 19.2 (6.9) 20.1 (9.2)  20.7 (10.2) 21.2 (8.4) 0.24 0.55 
Chromium Cobalt, CoCr; Stainless Steel, SS 
Count data shown as: count (%); comparisons: Fisher's exact test 
Numeric data shown as: mean (SD); comparisons: independent samples t-test 
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Table 2.  Vessel measurements (target lesion) 
 
 Placebo  Prednisolone  Drug  Stent 
 CoCr   SS   CoCr   SS   Prednisolone-Placebo  SS-CoCr 
 Mean SD  Mean SD  Mean SD  Mean SD  Diff. 95% CI p  Diff. 95% CI p 
Reference diameters, mm                     
Pre-PCI 3.19 (0.41)  3.13 (0.43)  3.21 (0.44)  3.21 (0.41)  0.06 -0.03 0.15 0.21  -0.03 -0.13 0.06 0.51 
Post-PCI 3.24 (0.39)  3.13 (0.39)  3.29 (0.43)  3.27 (0.35)  0.10 0.01 0.19 0.03  -0.07 -0.16 0.02 0.13 
                      
6-month 3.05 (0.42)  3.02 (0.40)  3.08 (0.43)  3.09 (0.37)  0.05 -0.04 0.15 0.28  -0.02 -0.11 0.08 0.75 
Minimum luminal diameters, mm                     
Pre-PCI [A] 0.97 (0.46)  0.93 (0.41)  0.95 (0.46)  0.95 (0.41)  0.00 -0.10 0.10 0.99  -0.02 -0.11 0.08 0.74 
Post-PCI [B] 3.02 (0.33)  2.98 (0.37)  3.04 (0.42)  3.04 (0.35)  0.05 -0.04 0.13 0.29  -0.03 -0.11 0.06 0.50 
6-month [C] 2.04 (0.49)  1.91 (0.62)  1.96 (0.57)  2.05 (0.57)  0.03 -0.10 0.17 0.61  -0.01 -0.14 0.12 0.87 
Acute Gain [B]-[A] 2.05 (0.50)  2.04 (0.47)  2.10 (0.54)  2.09 (0.47)  0.05 -0.06 0.16 0.42  -0.01 -0.12 0.10 0.85 
Late loss [B]-[C] 0.95 (0.37)  1.08 (0.56)  1.13 (0.53)  0.99 (0.50)  0.04 -0.08 0.16 0.49  -0.02 -0.13 0.10 0.79 
Net gain [A]-[C] 0.97 (0.59)  1.08 (0.58)  1.10 (0.62)  1.03 (.68)  0.04 -0.10 0.19 0.57  -0.01 -0.16 0.13 0.87 
Diameter stenosis, %                      
Pre-PCI 69.6% (14.0%)  70.1% (12.6%)  70.5% (13.8%)  70.7% (11.2%)  0.7% -2.1% 3.6% 0.62  0.3% -2.5% 3.2% 0.83 
Post-PCI  6.9% (6.4%)  5.1% (5.2%)  7.2% (6.6%)  7.1% (5.6%)  1.3% 0.0% 2.6% 0.06  -1.0% -2.3% 0.4% 0.15 
6-month  33.4% (12.3%)  36.6% (18.7%)  36.5% (16.2%)  33.9% (15.3%)  0.1% -3.6% 3.8% 0.97  0.0% -3.7% 3.7% 0.98 
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Table 3. Study events 
 
 Placebo, N=145     Prednisolone, N=170   Drug   Stent  
 CoCr, n=65  SS, n=80  CoCr, n=90  SS, n=80  Placebo Pred.   CoCr SS  
 Count %  Count %  Count %  Count %  % % p  % % p 
Primary endpoint*                    
Restenosis (by any measure)+ 7 (11.7%)  19 (26.4%)  18 (22.8%)  13 (17.1%)  19.7% 20.0% 1.00  18.0% 21.6% 0.46 
in-segment average 7 (11.7%)  19 (26.4%)  18 (22.8%)  13 (17.1%)  19.7% 20.0% 1.00  18.0% 21.6% 0.46 
Secondary endpoints                    
Target lesion revascularisation 1 (1.5%)  9 (11.2%)  5 (5.6%)  6 (7.5%)  6.9% 6.5% 1.00  3.9% 9.4% 0.07 
Target vessel revascularisation 2 (3.1%)  9  (11.2%)  6 (6.7%)  6 (7.5%)  7.6% 7.1% 1.00  5.2% 9.4% 0.19 
Any endpoint or SAE 8 (12.3%)   20 (25.0%)   20 (22.2%)   13 (16.3%)   19.3% 19.4% 1.00   18.1% 20.6% 0.67 
MACCE                    
composite 2 (3.1%)  10 (12.5%)  6 (6.7%)  6 (7.5%)  8.3% 7.1% 0.83  5.2% 10.0% 0.14 
death 0 (0.0%)  1 (1.3%)  1 (1.1%)  0 (0.0%)  0.7% 0.6% 1.00  0.6% 0.6% 1.00 
MI 1 (1.5%)  1 (1.3%)  1 (1.1%)  0 (0.0%)  1.4% 0.6% 0.60  1.3% 0.6% 0.62 
CVA 0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0.0% 0.0% -  0.0% 0.0% - 
Target vessel revascularisation 2 (3.1%)  9 (11.3%)  6 (6.7%)  6 (7.5%)  7.6% 7.1% 1.00  5.2% 9.4% 0.19 
Count data shown as: count (%); comparisons: group %, Fisher's exact test 
* Analysed as target lesion (i.e. one lesion per patient) + 287 patients completed final follow-up angiography (CoCr /Placebo, n=60; SS/Placebo=72; CoCr/Prednisolone=79; SS/Prednisolone=76) 
MACCE, major adverse cardiovascular cerebrovascular events; MI, myocardial infarction; CVA, cerebrovascular accident 
  
23 
 
Table 4. Study markers 
 Placebo  Prednisolone  Drug   Stent  
 CoCr  SS  CoCr  SS  Prednisolone-Placebo SS- CoCr 
 Mean SD  Mean SD  Mean SD  Mean SD  95% CI p  95% CI p 
hs-CRP, mg/L                                  
admission 6.31 (14.53)  8.32 (13.11)  5.39 (11.77)  6.36 (15.07)  -4.90 1.72 0.35  -1.73 4.83 0.35 
pre-procedure 5.36 (12.77)  6.66 (10.50)  4.51 (11.32)  6.69 (15.19)  -3.56 2.53 0.74  -1.22 4.83 0.24 
7 days 7.25 (9.38)  7.57 (16.14)  1.86 (6.99)  0.96 (3.01)  -8.35 -3.61 <0.001  -2.31 2.62 0.90 
30 days 4.11 (9.85)  3.33 (6.38)  5.79 (6.56)  7.03 (9.43)  0.78 4.65 0.006  -1.79 2.12 0.87 
6 months 1.48 (1.77)  3.29 (4.31)  2.45 (4.51)  4.36 (12.82)  -1.09 2.79 0.39  -0.15 3.69 0.07 
HbA1c, %                    
admission 5.75 (0.85)  5.86 (0.97)  5.83 (0.87)  5.71 (0.50)  -0.23 0.16 0.75  -0.21 0.18 0.88 
7 days 5.76 (0.84)  5.81 (0.89)  5.97 (0.99)  5.88 (0.53)  -0.05 0.34 0.16  -0.23 0.16 0.73 
30 days 5.72 (0.67)  5.75 (0.60)  6.01 (1.24)  5.95 (0.55)  0.05 0.44 0.016  -0.23 0.16 0.73 
6 months 5.75 (0.67)  5.95 (0.83)  5.96 (1.14)  5.82 (0.51)  -0.17 0.24 0.75  -0.19 0.23 0.85 
Time to 30d FU (d) 37.6 (104.5)  32.6 (6.9)  40.9 (79.0)  28.4 (41.6)  -15.1 15.2 1.00  -24.0 6.1 0.24 
Time to 6m FU (d) 210 (37)  204 (37)  203 (34)  201 (28)  -12.9 3.0 0.22  -11.3 4.6 0.41 
 
